Keywords: Alzheimer's Disease, Alzheimer's Disease
Motivation: Developing imaging tools for these hallmarks is important for the diagnosis and treatment of Alzheimer’s disease (AD).
Goal(s): To evaluate MRI signal changes in different mouse models and the time-dependent signal changes using our novel gadolinium (Gd)-dodecane tetraacetic acid (DOTA)- ob5 aptamer contrast agent.
Approach: We developed an MRI contrast agent by conjugating Gd-DOTA-DNA aptamer called ob5. A total of 10 control mice, 9 3xTg AD mice, and 11 APP/PS/Tau AD mice were included in this study.
Results: The signal enhancement peaked around 15 to 20 minutes after injection of the contrast agent.
Impact: Our novel contrast agent targeting oAβ has the potential ability to diagnose early AD and monitor the progression of AD.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords